DF Safety AI – Demo

DF Safety AI is a modern cloud-based Safety Platform, that uses the power of AI/ML to deliver efficiencies and a great user experience in Safety Case [...]

Efficiency of case intake is critical to safety vigilance operations. However, the conventional approach of receiving the safety case information from various sources, and performing a manual case entry in a safety database, is time consuming. In the current scenario where there is a significant increase in the number of adverse events being reported for drugs, vaccines, cosmetics and devices, manual case creation process increases costs and creates compliance issues. Automation of safety case intake is therefore an imperative, but most of the safety platforms in the market make it very hard to implement automation during case creation and processing.

Safety concerns associated with therapeutic intervention(s) and immunizations can be detected, analyzed, and minimized only through early identification and having proper risk minimization measures throughout the life cycle of a drug. Researchers face multiple challenges while designing the right strategies for early detection of safety signals. Safety concerns can arise throughout the lifecycle of a drug, broadly divided into pre-market clinical development and post marketing surveillance activities.

The pharmaceutical industry is advancing at an unprecedented pace, with new drugs and therapies continually emerging to improve patient outcomes. Yet, the critical focus on patient safety has never been more intense. For small and medium-sized pharmaceutical companies, this presents both an opportunity and a challenge. The opportunity lies in delivering innovative and safe medicines to the market, while the challenge is to ensure that safety practices are on par with the industry giants. This is where drug safety automation, particularly with the likes of DF Safety AI, can transform the landscape. In this blog, we will delve into the world of drug safety automation and explore how it can empower small and medium pharma companies in the realms of people, process, and system.

The pharmaceutical sector has grown significantly in recent years as a result of digitization and greater research, and it is expected to be worth $1.5 trillion by 2023 according to estimates. The Clinical Pharmacology and Therapeutics Journal has published an research about the use of AI/ML techniques in drug development, regulatory submissions, review, and research. Pharmacovigilance is crucial for post-marketing safety and effectiveness investigations since it assures the safety profile of biological products throughout medication development. AI/ML is being researched to increase the efficiency and efficacy of the pharmacovigilance process, with multiple areas of application identified. These technologies are helping to automate labor-intensive and repetitive tasks and improve the accuracy and speed of drug safety monitoring.

We are thrilled to announce a new release of DF Safety AI, the most advanced safety vigilance solution that enables digital transformation of pharmacovigilance. DF Safety AI is an AI powered platform that uses advanced AI/ML technologies and automation to deliver efficiencies and an exceptional user experience across Drugs, Cosmetics, Vaccines, Nutraceuticals and Medical Devices. With an enhanced, in-built E2B R2/R3 compliant data import and export, DF Safety AI offers a seamless integration with other safety related applications and databases. A new feature enables bulk migration of case data using XML, allowing for the transfer of large amounts of data in a secure and efficient manner. The newly introduced Product and Study Configuration module allows the configuration of study details and products, ensuring the unique needs of customers are managed efficiently.

The Drug Safety and Clinical Data Quality Act is a U.S. law that is meant to provide the FDA with more authority to regulate and enforce drug safety for consumers, as well as monitor clinical trials. The Act was enacted in 2012 and is currently enforced under the FDA’s Center for Drug Evaluation and Research (CDER).